
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Vor Biopharma Inc (VOR)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VOR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $1.18
1 Year Target Price $1.18
0 | Strong Buy |
0 | Buy |
5 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.3% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 250.75M USD | Price to earnings Ratio - | 1Y Target Price 1.18 |
Price to earnings Ratio - | 1Y Target Price 1.18 | ||
Volume (30-day avg) 5 | Beta 2.06 | 52 Weeks Range 0.13 - 3.29 | Updated Date 08/15/2025 |
52 Weeks Range 0.13 - 3.29 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.68 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.2243 | Actual -12.56 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -132.36% | Return on Equity (TTM) -125.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 50182215 | Price to Sales(TTM) - |
Enterprise Value 50182215 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.09 | Shares Outstanding 126640000 | Shares Floating 47588511 |
Shares Outstanding 126640000 | Shares Floating 47588511 | ||
Percent Insiders 42.84 | Percent Institutions 45.37 |
Upturn AI SWOT
Vor Biopharma Inc
Company Overview
History and Background
Vor Biopharma Inc. was founded in 2016. It is a clinical-stage cell therapy company pioneering engineered hematopoietic stem and progenitor cells (HSPCs) to create next-generation, off-the-shelf therapies for hematological malignancies. Significant milestones include IND clearance for lead candidate VOR33 and initiation of clinical trials.
Core Business Areas
- Engineered HSPCs: Vor Biopharma's core business revolves around developing and commercializing engineered HSPCs. They are focused on making allogeneic stem cell transplants safer and more effective for patients with blood cancers.
- VOR33 Clinical Program: The clinical trial for VOR33, their lead product, focuses on acute myeloid leukemia (AML). It's designed to deplete CD33-expressing cells to enable safer and more effective transplantation.
Leadership and Structure
Robert Ang, M.D., Ph.D. is the President and Chief Executive Officer. The company has a typical structure for a clinical-stage biotech company, with departments focused on research, clinical development, manufacturing, and corporate functions.
Top Products and Market Share
Key Offerings
- VOR33: VOR33 is Vor Biopharma's lead product candidate, engineered HSPCs designed to be insensitive to Mylotarg (gemtuzumab ozogamicin), an anti-CD33 antibody-drug conjugate. It is currently in clinical trials for AML. Market share data is not yet applicable as it is pre-commercial. Competitors developing AML treatments include AbbVie (Venclexta), Novartis (Rydapt), and other companies developing stem cell transplantation technologies.
Market Dynamics
Industry Overview
The industry is characterized by intense research and development, high regulatory hurdles, and a competitive landscape. Advances in cell and gene therapy are creating new opportunities for treating previously untreatable diseases. There is a growing demand for more effective and safer treatments for hematological malignancies.
Positioning
Vor Biopharma is positioned as an innovator in engineered HSPC technology, seeking to overcome limitations of traditional stem cell transplantation. Its competitive advantage lies in its specific targeting of CD33-expressing cells and its potential to improve outcomes for AML patients.
Total Addressable Market (TAM)
The global AML market is expected to reach approximately $3.5 billion by 2028. Vor Biopharma is positioned to capture a portion of this market through its novel approach to stem cell transplantation.
Upturn SWOT Analysis
Strengths
- Novel engineered HSPC technology
- Targeted approach to CD33-expressing cells
- Strong intellectual property position
- Experienced management team
Weaknesses
- Clinical-stage company with no revenue-generating products
- High cash burn rate
- Reliance on clinical trial success
- Small market capitalization
Opportunities
- Successful clinical trials and regulatory approval of VOR33
- Expansion of platform technology to other hematological malignancies
- Partnerships with pharmaceutical companies
- Potential for acquisition by a larger company
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other cell therapy companies
- Development of alternative AML treatments
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BLUE
Competitive Landscape
Vor Biopharma faces competition from other companies developing cell and gene therapies for hematological malignancies. Its advantage lies in its unique approach to engineered HSPCs and its focus on CD33 depletion.
Growth Trajectory and Initiatives
Historical Growth: Vor Biopharma's growth has been driven by the advancement of its VOR33 clinical program and the expansion of its engineered HSPC platform.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approval of VOR33. Analyst estimates vary widely, reflecting the uncertainty associated with drug development.
Recent Initiatives: Recent initiatives include advancing the VOR33 Phase 1/2 clinical trial, expanding the company's manufacturing capabilities, and exploring potential partnerships.
Summary
Vor Biopharma is a clinical-stage company with a promising engineered HSPC technology targeting AML. Its success is highly dependent on the outcome of clinical trials for VOR33. The company has a strong intellectual property position but faces the risks associated with drug development, including regulatory hurdles and competition. The company needs to focus on making clinical advances in trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry news sources
- Vor Biopharma Investor Relations website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vor Biopharma Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-02-05 | Chairman & CEO Dr. Jean-Paul Kress M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 159 | Website https://www.vorbio.com |
Full time employees 159 | Website https://www.vorbio.com |
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.